Literature DB >> 7504327

A human monoclonal antibody, produced following in vitro immunization, recognizing an epitope shared by HLA-A2 subtypes and HLA-A28.

A Mulder1, M Kardol, J Blom, W B Jolley, C J Melief, H Bruning.   

Abstract

In vitro immunization and subsequent immortalization of peripheral blood cells of a multiparous woman has resulted in the production of a stable human mouse heterohybridoma, 5C2A2, secreting an HLA-A2/A28-specific human monoclonal antibody. Although possibly exposed to HLA-A2 by transfusions, the cell donor showed no HLA-A2-specific serum antibodies. The present protocol for in vitro immunization includes the elimination of suppressor cells from the responder cell population, the presence of irradiated allogeneic lymphocytes as a source of antigen, as well as stimuli--recombinant interleukin-2 and a B-cell specific nucleoside analogue--causing the proliferation of B lymphocytes, prior to immortalization. The ability of the antibody 5C2A2 to detect all known HLA-A2 subtypes, except A2.3, and A28, allows identification of the serological epitope on the HLA-A2 molecule. Application of this in vitro immunization method allows the production of a set of HLA monoclonal antibody-secreting human hybridomas, independent of the existence of serum HLA antibodies in the lymphocyte donors.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7504327     DOI: 10.1111/j.1399-0039.1993.tb02162.x

Source DB:  PubMed          Journal:  Tissue Antigens        ISSN: 0001-2815


  6 in total

1.  Monocyte recruitment by HLA IgG-activated endothelium: the relationship between IgG subclass and FcγRIIa polymorphisms.

Authors:  N M Valenzuela; K R Trinh; A Mulder; S L Morrison; E F Reed
Journal:  Am J Transplant       Date:  2015-02-03       Impact factor: 8.086

2.  High-resolution analysis of HLA class I alterations in colorectal cancer.

Authors:  Jan Willem F Dierssen; Noel F C C de Miranda; Arend Mulder; Marjo van Puijenbroek; Willem Verduyn; Frans H J Claas; Cornelis J H van de Velde; Gert Jan Fleuren; Cees J Cornelisse; Willem E Corver; Hans Morreau
Journal:  BMC Cancer       Date:  2006-10-02       Impact factor: 4.430

3.  An Anti-C1s Monoclonal, TNT003, Inhibits Complement Activation Induced by Antibodies Against HLA.

Authors:  K A Thomas; N M Valenzuela; D Gjertson; A Mulder; M C Fishbein; G C Parry; S Panicker; E F Reed
Journal:  Am J Transplant       Date:  2015-04-22       Impact factor: 8.086

4.  Complement-Mediated Enhancement of Monocyte Adhesion to Endothelial Cells by HLA Antibodies, and Blockade by a Specific Inhibitor of the Classical Complement Cascade, TNT003.

Authors:  Nicole M Valenzuela; Kimberly A Thomas; Arend Mulder; Graham C Parry; Sandip Panicker; Elaine F Reed
Journal:  Transplantation       Date:  2017-07       Impact factor: 4.939

5.  Recombinant human monoclonal HLA antibodies of different IgG subclasses recognising the same epitope: Excellent tools to study differential effects of donor-specific antibodies.

Authors:  Cynthia S M Kramer; Marry E I Franke-van Dijk; Ashley J Priddey; Tamás Pongrácz; Elena Gnudi; Helena Car; Gonca E Karahan; Els van Beelen; Chalana C C Zilvold-van den Oever; Hendrik J Rademaker; Noortje de Haan; Manfred Wuhrer; Vasilis Kosmoliaptsis; Paul W H I Parren; Arend Mulder; Dave L Roelen; Frans H J Claas; Sebastiaan Heidt
Journal:  HLA       Date:  2019-08-25       Impact factor: 4.513

6.  A Comprehensive Evaluation of the Antibody-Verified Status of Eplets Listed in the HLA Epitope Registry.

Authors:  Suzanne Bezstarosti; Kim H Bakker; Cynthia S M Kramer; Johan W de Fijter; Marlies E J Reinders; Arend Mulder; Frans H J Claas; Sebastiaan Heidt
Journal:  Front Immunol       Date:  2022-01-28       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.